KHK7580
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism
Trial Timeline
May 1, 2014 → Dec 1, 2014
NCT ID
NCT02143271About KHK7580
KHK7580 is a phase 1 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02143271. Target conditions include Secondary Hyperparathyroidism.
What happened to similar drugs?
13 of 20 similar drugs in Secondary Hyperparathyroidism were approved
Approved (13) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03280264 | Phase 3 | Completed |
| NCT02549417 | Phase 3 | Completed |
| NCT02549404 | Phase 3 | Completed |
| NCT02143271 | Phase 1 | Completed |
| NCT01935856 | Phase 1/2 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism